Abstract
Obesity is a major global health problem and is associated with increased cardiometabolic morbidity and mortality. Protein glycosylation is a frequent posttranslational modification, highly responsive to numerous pathophysiological conditions and aging. The prospect of biological age reduction, by reverting glycosylation changes through metabolic intervention, opens many possibilities. We have investigated whether weight loss interventions affect inflammation- and aging-associated IgG glycosylation changes, in a longitudinal cohort of bariatric surgery patients. To support potential findings, BMI-related glycosylation changes were monitored in a longitudinal twins cohort. IgG N-glycans were chromatographically profiled in 37 obese patients, subjected to a low-calorie diet, followed by bariatric surgery, across multiple timepoints. Similarly, plasma-derived IgG N-glycan traits were longitudinally monitored in 1,680 participants from the TwinsUK cohort. Low-calorie diet induced a marked decrease in the levels of IgG N-glycans with bisecting GlcNAc, whose higher levels are usually associated with aging and inflammatory conditions. Bariatric surgery resulted in extensive alterations of the IgG glycome that accompanied progressive weight loss during a one-year follow-up. We observed a significant increase in digalactosylated and sialylated glycans, and a substantial decrease in agalactosylated and core fucosylated IgG glycans. In general, this IgG glycan profile is associated with younger biological age and reflects an enhanced anti-inflammatory IgG potential. Loss of BMI over a 20 year period in the TwinsUK cohort validated a weight loss-associated agalactosylation decrease and an increase in digalactosylation. Altogether, these findings highlight that weight loss substantially affects IgG N-glycosylation, resulting in reduced biological and immune age.
Competing Interest Statement
GL declares that he is a founder and owner of Genos Glycoscience Ltd, which offers commercial service of glycomic analysis and has several patents in this field. TŠ, HD, ACi, FV and OG are employees of Genos Glycoscience Ltd.
Funding Statement
Glycosylation analysis was performed in Genos Glycoscience Research Laboratory and partly supported by the European Union's Horizon 2020 grants Backup (grant# 777090), European Structural and Investment Funds IRI grant (#KK.01.2.1.01.0003), Centre of Competence in Molecular Diagnostics (#KK.01.2.2.03.0006) and Croatian National Centre of Research Excellence in Personalized Healthcare grant (#KK.01.1.1.01.0010). Bariatric research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Gastroenterology and Mucosal Immunity Theme to CVA-C and VLG, Oxford Biomedical Research Centre Diabetes and Metabolism theme for JWT, MRC programme grant to JWT (ref. MR/P011462/1), the NIHR Research Capability Funding to VLG and AG, the Wellcome Trust (101734/Z/13/Z) to AG. NJD is supported by a University of Oxford Novo Nordisk Clinical Research Fellowship. TwinsUK received funding from the Wellcome Trust European Communitys Seventh Framework Programme (FP7/2007-2013 to TwinsUK); the National Institute for Health Research (NIHR) Clinical Research Facility at Guys & St Thomas NHS Foundation Trust and the Nottingham NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. CM is funded by the MRC AimHy (MR/M016560/1) project grant and by the Chronic Disease Research Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained by the National Research Ethics Committees of the UK National Health Service (NHS) under the reference number 16/YH/0247. All individuals participating in this study gave written informed consent. The TwinsUK study was approved by NRES Committee London Westminster, and all twins provided informed written consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.
